deamidation is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-12-08. Where a claim depends on a specific study, the study is described rather than over-claimed.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
The peptide activates two G protein-coupled receptors, GIPR and GLP-1R. Binding triggers adenylyl cyclase activity and raises intracellular cyclic AMP in pancreatic beta cells, which potentiates insulin release when glucose is elevated. Signaling in the central nervous system is associated with reduced appetite and lower energy intake, while effects on gastric emptying and glucagon secretion are also reported. Because activity at both receptors is retained, the pharmacological profile is often described as incretin-based rather than selective for a single receptor.
After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Dual GIP/GLP-1 receptor agonist |
| Amino acid count | 39 | Contains non-natural residues |
| Modification | C20 fatty diacid | Attached via linker; promotes albumin binding |
| Half-life | Approximately 5 days | Supports once-weekly dosing |
| Primary route | Subcutaneous injection | Not for intravenous use |
Regulatory and quality discussions place the peptide within established guidance for synthetic peptides and biologics. Forced degradation studies, in which samples are exposed to heat, acid, base, peroxide, and light, identify likely degradation products and validate the selectivity of analytical methods. Reference standards allow comparison across laboratories and production batches. Purity specifications reported in the literature usually combine chromatographic purity with mass confirmation. Which impurity thresholds are meaningful for long-term behavior is still debated, and no single universal specification has been adopted across all jurisdictions.
Routine characterization of the peptide relies on reversed-phase high-performance liquid chromatography for purity assessment, usually with ultraviolet detection near 214 nanometers. Intact mass measurement by liquid chromatography coupled to mass spectrometry confirms molecular identity against a theoretical value. Sequence-level confirmation uses enzymatic digestion followed by tandem mass spectrometry, an approach known as peptide mapping. Amino acid analysis gives an independent check on composition. Circular dichroism spectra are used to estimate helical content in aqueous buffer.
Stability depends strongly on physical form. The dry powder is generally regarded as stable for extended periods when held at or below minus twenty degrees Celsius in a sealed, desiccated container. In solution, degradation pathways include deamidation of asparagine and glutamine residues, oxidation of methionine, and aggregation. Reaction rates for these pathways rise with temperature. Repeated freezing and thawing of solutions promotes aggregation, and light exposure can accelerate some oxidative changes. Buffer composition and pH influence which pathway dominates at a given temperature.
At the receptor level, the compound binds both GIP and GLP-1 receptors and triggers downstream signalling that raises cyclic AMP in target cells. GLP-1 receptor activation is associated with glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. GIP receptor activation contributes effects that are less completely characterised, and how much each receptor adds to the overall clinical response is still an open question. The two pathways appear to interact in a complementary rather than a purely additive way.
An extended fatty diacid moiety promotes binding to serum albumin, which slows renal clearance and extends the circulating half-life to roughly five days. That property supports once-weekly administration and largely explains the dosing interval described in clinical reports. Published data come mainly from large randomised programmes that evaluated glycaemic control and body weight over periods of many months. Long-term outcomes beyond those trial windows, including what happens after treatment stops, remain an active area of investigation.
Identity and purity of tirzepatide are assessed mainly by reversed-phase high-performance liquid chromatography with ultraviolet detection, often paired with mass spectrometry. Because the molecule carries several modifications, gradient conditions are adjusted to resolve the intact peptide from deamidation and oxidation products. Enzymatic digestion followed by peptide mapping confirms the primary sequence and locates specific modifications. Quantitation in biological matrices typically uses liquid chromatography with tandem mass spectrometry after solid-phase extraction. Immunoassays are used less often, since antibody cross-reactivity with closely related peptides can bias results.
The peptide shares degradation routes common to modified peptides: deamidation of asparagine and glutamine residues, oxidation of methionine, and backbone hydrolysis under extreme pH. Lyophilized material is generally more stable than a solution, and residual water content directly affects the rate of hydrolysis. In liquid form, aggregation and visible particles can appear after agitation or repeated freeze-thaw cycles. Stability studies therefore track monomer content, aggregate content, and potency over months under defined temperature and humidity.
== Causes == Prolidase deficiency is the result of mutations on the PEPD gene which is located on the "q", i.e., long, arm of chromosome 19 at region 1, band 3, sub-band 11 (notated as 19q13.11). This gene codes for the prolidase Enzyme, also known as peptidase-D. At least 19 different mutations in the PEPD gene have been identified in individuals affected by the disorder.
Properties also decrease with the age of the fiber. Younger fibers tend to be stronger and more elastic than older ones. Many natural fibers exhibit strain rate sensitivity due to their viscoelastic nature. Bone contains collagen and exhibits strain rate sensitivity in that the stiffness increases with strain rate, also known as strain hardening. Spider silk has hard and elastic regions that together contribute to its strain rate sensitivity, these cause the silk to exhibit strain hardening as well. Properties of natural fibers are also dependent on the moisture content in the fiber.
A synthetic, radioactive element, curium is a hard, dense metal with a silvery-white appearance and physical and chemical properties resembling gadolinium. Its melting point of 1344 °C is significantly higher than that of the previous elements neptunium (637 °C), plutonium (639 °C) and americium (1176 °C). In comparison, gadolinium melts at 1312 °C. Curium boils at 3556 °C. With a density of 13.52 g/cm3, curium is lighter than neptunium (20.45 g/cm3) and plutonium (19.8 g/cm3), but heavier than most other metals. Of two crystalline forms of curium, α-Cm is more stable at ambient conditions. It has a hexagonal symmetry, space group P63/mmc, lattice parameters a = 365 pm and c = 1182 pm, and four formula units per unit cell. The crystal consists of double-hexagonal close packing with the layer sequence ABAC and so is isotypic with α-lanthanum. At pressure >23 GPa, at room temperature, α-Cm becomes β-Cm, which has face-centered cubic symmetry, space group Fm3m and lattice constant a = 493 pm. On further compression to 43 GPa, curium becomes an orthorhombic γ-Cm structure similar to α-uranium, with no further transitions observed up to 52 GPa. These three curium phases are also called Cm I, II and III. Curium has peculiar magnetic properties. Its neighbor element americium shows no deviation from Curie-Weiss paramagnetism in the entire temperature range, but α-Cm transforms to an antiferromagnetic state upon cooling to 65–52 K, and β-Cm exhibits a ferrimagnetic transition at ~205 K.
=== Venom === Rattlesnake venom is hemotoxic, destroying tissue, causing necrosis and coagulopathy (disrupted blood clotting). In the U.S., the tiger rattlesnake (C. tigris) and some varieties of the Mojave rattlesnake (C. scutulatus) also have a presynaptic neurotoxic venom component known as Mojave type A toxin, which can cause severe paralysis. However, most North American rattlesnakes are not neurotoxic. Although it has a comparatively low venom yield, the venom toxicity of C. tigris is considered to be among the highest of all rattlesnake venoms, and among the highest of all snakes in the Western Hemisphere based on LD50 studies conducted on laboratory mice. C. scutulatus is also widely regarded as producing one of the most toxic snake venoms in the Americas, based on LD50 studies in laboratory mice. Rattlesnake venom is a mixture of five to fifteen enzymes, various metal ions, biogenic amines, lipids, free amino acids, proteins, and polypeptides. More specifically, there are three main families of toxins in rattlesnakes: phospholipases A2 (PLA2s), snake venom metalloproteinases (SVMPs), and snake venom serine proteinases (SVSPs). It contains components meant to immobilize and disable the prey, as well as digestive enzymes, which break down tissue to prepare for later ingestion. The venom is very stable, and retains its toxicity for many years in storage. Snake venom, in general, has a complex and ongoing evolutionary process, and rattlesnake venom is no different. The primary mechanisms of evolution are both gene duplication and gene loss events.
Sources: en.wikipedia.org
A new French commander in chief and high commissioner, General Jean Marie de Lattre de Tassigny, was appointed in December 1950. With him began the construction of a defensive line of fortifications around the Red River Delta, to protect against Việt Minh incursions and against a possible Chinese invasion. It became known as the De Lattre Line. In 1950 and 1951, de Lattre implemented scorched earth tactics in an effort to limit Việt Minh access to food and other supplies. French forces burned crops in areas of Việt Minh activity. These tactics increased the anger of the Vietnamese people against the French and were a strategic failure. In late 1950 Giáp decided to go on a "general counteroffensive", seeking the final defeat of the French. On January 13, 1951, he moved the 308th and 312th Divisions, with more than 20,000 men, to attack Vĩnh Yên, 30 miles (48 km) northwest of Hanoi, which was manned by 6,000 French troops. Considered the first set-piece battle of the war, the Vietnamese saw initial success, although as the battle progressed, French aerial supremacy proved decisive as reinforcements flew in from the rest of Indochina and all available aircraft capable of dropping bombs was utilized to carry out what would be the largest aerial bombardment of the war. By noon of January 17, Giáp's troops withdrew in defeat. The Vietnamese had suffered 5,000–6,000 deaths and 500 combatants were captured. Giáp tried again to break the French defensive line, this time 20 miles (32 km) north-east of Haiphong in an attempt to cut the French access to the port city.
=== Ligase concentration === As is usual for an enzyme, the higher the ligase concentration, the faster is the rate of ligation. Blunt-end ligation is much less efficient than sticky end ligation, so a higher concentration of ligase is used in blunt-end ligations. High DNA ligase concentration may be used in conjunction with PEG for a faster ligation, and they are the components often found in commercial kits designed for rapid ligation.
==== Extracellular phenoloxidases ==== Phenols are an important group of ecotoxins due to their toxicity and persistence. Many microorganisms can degrade aromatic pollutants and use them as a source of energy, and the ability of microalgae to degrade a multitude of aromatic compounds including phenolic compounds is increasingly recognized. Some microalgae including Chlamydomonas sp., Chlorella sp., Scenedesmus sp. and Anabaena sp. are able to degrade various phenols such as pentachlorophenol, p-nitrophenol, and naphthalenesulfonic acids. Though the metabolic degradation pathways are not fully understood, enzymes including phenoloxidase laccase (EC 1.10.3.2) and laccase-like enzymes are involved in the oxidation of aromatic substrates. These exoenzymes can be potentially applied in the environmental degradation of phenolic pollutants.
=== Sales === According to Newell, Half-Life was budgeted with the expectation of lifetime sales of around 180,000 copies. However, it was a surprise hit. In the United States, it debuted at #8 on PC Data's weekly PC game sales chart for the November 15–21 period, with an average retail price (ARP) of $49. It rose to sixth place the following week, before dropping to position 10 for the week ending December 5. During the December 6–12 period, the game climbed back to sixth place; by this time, its ARP had dropped to $36. It placed between sixth and eighth on PC Data's weekly charts through the end of December, and its ARP rose back to $45 by the week ending January 2. PC Data declared Half-Life November's sixth-best-selling PC game in the United States, a position it held for the month of December. While its U.S. sales were below 100,000 copies by November 30, it sold 212,173 copies and earned revenues of $8.6 million in the United States by the end of 1998. In January 1999, Half-Life debuted at #3 on Chart-Track's PC game sales rankings for the United Kingdom, and remained in PC Data's weekly top 10 for the entire month, peaking at #4. By January 19, after two full months of availability, global sales of Half-Life surpassed 500,000 units. In the United States, it was the fifth-best-selling PC game for the month of January. On PC Data's weekly charts, it rose to #2 from February 7–20, with an ARP of $35. Holding a position in the weekly top 10 for the rest of February, it climbed to fourth for the month.
Hyperthyroidism and hypothyroidism are the two major dysfunctions associated to behavioral and brain chemistry changes due to the imbalances in the thyroid hormones, triiodothyronine (T3) and thyroxine (T4).
Sources: en.wikipedia.org
It activates both GIP and GLP-1 receptors. This dual action differentiates it from selective GLP-1 agonists.
It is given as a subcutaneous injection. Its long half-life supports weekly dosing.
No, it is synthetic. It contains non-natural amino acids and a fatty acid modification.
It is a synthetic linear peptide that acts as a dual agonist at the GIP and GLP-1 receptors. It combines a modified incretin backbone with a fatty diacid side chain that extends its circulation time. It is not a small-molecule drug and is not orally absorbed in its native form.